Drug	Sched ule
Ethylmorphone (9190)	             
Morphine (9300)	       

The firm plans to manufacture small quantities of the listed controlled substances to produce standards for analytical laboratories.

DĚA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Iostec, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated the company on a regular basis to ensure that its continued registration is consistent with the public interest. These investigations have included inspection and testing of the company's physical security systems, audits of the company's records, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: May 12, 2000.

### John H. King,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 00–12842 Filed 5–22–00; 8:45 am] **BILLING CODE 4410–09–M** 

## **DEPARTMENT OF JUSTICE**

#### **Drug Enforcement Administration**

# Manufacturer of Controlled Substances; Notice of Registration

By notice dated February 10, 2000, and published in the **Federal Register** on February 17, 2000, (65 FR 33), Novartis Pharmaceutical Corporation, 59 Route 10, East Hanover, New Jersey 07926, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of methylphenidate

(1724), a basic class of controlled substance listed in Schedule II.

The firm plans to manufacture finished product for distribution to its customers.

DEA has considered the factors in title 21, United States Code, section 823(a) and determined that the registration of Novartis Pharmaceutical Corporation to manufacture methylphenidate is consistent with the public interest at this time. DEA has investigated Novartis Pharmaceutical Corporation on a regular basis to ensure that the company's continued registration is consistent with the public interest. These investigations have included inspection and testing of the company's physical security systems, audits of the company's records, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed above is granted.

Dated: May 12, 2000.

### John H. King,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 00–12841 Filed 5–22–00; 8:45 am] BILLING CODE 4410–09–M

## **DEPARTMENT OF JUSTICE**

## **Drug Enforcement Administration**

## Manufacturer of Controlled Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 30, 2000, Radian International LLC, 14050 Summit Drive #121, P.O. Box 201088, Austin, Texas 78720–1088, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Sched- ule
Cathinone (1235)	 
4-Methylaminorex (cis isomer)	i
(1590).	
Methagualone (2565)	l I

Drug	Sche
Alpha-Ethyltryptamine (7249)	ı
Lysergic acid diethylamide (7315)	!
Tetrahydrocannabinols (7370) Mescaline (7381)	
3,4,5-Trimethoxyamphetamine	i
(7390). 4-Bromo-2,5-dimethoxyamphetamine	I
(7391). 4-Bromo-2,5-	ı
dimethoxyphenethylamine (7392).	
4-Methyl-2,5-dimethoxyamphetamine (7395).	
2,5-Dimethoxyamphetamine (7396)	1
2,5-Dimethoxy-4-ethylamphetamine (7399).	<b>'</b>
3,4-Methylenedioxyamphetamine	ı
(7400). 5-Methoxy-3,4-	ı
methylenedioxyamphetamine	
(7401). N-Hydroxy-3,4-	ı
methylenedioxyamphetamine	
(7402). 3,4-Methylenedioxy-N-	ı
ethylamphetamine (7404).	-
3,4- Methylenedioxymethamphetamine	I
(7405).	
4-Methoxyamphetamine (7411) Bufotenine (7433)	 
Diethyltryptamine (7434)	ļ!
Dimethyltryptamine (7435) Psilocybin (7437)	
Psilocyn (7438)	į
Acetyldihydrocodeine (9051) Benzylmorphine (9052)	H
Codeine-N-oxide (9053)	ļ į
Dihydromorphine (9145) Heroin (9200)	H
Morphine-N-oxide (9307)	l i
Normorphine (9313) Pholcodine (9314)	
Acetylmethadol (9601)	l i
Allyprodine (9602)	 
Alphacetylmethadol (9603).	'
Alphameprodine (9604)Alphamethadol (9605)	 
Betacetylmethadol (9607)	li i
Betameprodine (9608) Betamethadol (9609)	1
Betaprodine (9611)	li
Hydromorphinol (9627)	1
Noracymethadol (9633) Norlevorphanol (9634)	li
Normethadone (9635)	!
Trimeperidine (9646)Para-Fluorofentanyl (9812)	 
3-Methylfentanyl (9813)	!
Alpha-methylfentanyl (9814)Acetyl-alpha-methylfentanyl (9815)	
Beta-hydroxyfentanyl (9830)	!
Beta-hydroxy-3-methyfentanyl (9831) Alpha-Methylthiofentanyl (9832)	
3-Methylthiofentanyl (9833)	i
Thiofentanyl (9835) Amphetamine (1100)	 
Methamphetamine (1105)	II
Phenmetrazine (1631) Methylphenidate (1724)	II II
Amobarbital (2125)	
Pentobarbital (2270) Secobarbital (2315)	II II
0e000a101tai (2010)	11